Display options
Cite
Lee N, Spears ME, Carlisle AE, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020;39(35):5709-5720doi: 10.1038/s41388-020-01395-9.
Lee, N., Spears, M. E., Carlisle, A. E., & Kim, D. (2020). Endogenous toxic metabolites and implications in cancer therapy. Oncogene, 39(35), 5709-5720. https://doi.org/10.1038/s41388-020-01395-9
Lee, Namgyu, et al. "Endogenous toxic metabolites and implications in cancer therapy." Oncogene vol. 39,35 (2020): 5709-5720. doi: https://doi.org/10.1038/s41388-020-01395-9
Lee N, Spears ME, Carlisle AE, Kim D. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720. doi: 10.1038/s41388-020-01395-9. Epub 2020 Jul 24. PMID: 32709924; PMCID: PMC7452860.
Copy Download .nbib Format: NLM
Share it on

Oncogene. 2020 Aug;39(35):5709-5720. doi: 10.1038/s41388-020-01395-9. Epub 2020 Jul 24.

Endogenous toxic metabolites and implications in cancer therapy.

Oncogene

Namgyu Lee, Meghan E Spears, Anne E Carlisle, Dohoon Kim

Affiliations

  1. Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
  2. Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA, 01605, USA. [email protected].

PMID: 32709924 PMCID: PMC7452860 DOI: 10.1038/s41388-020-01395-9

Abstract

It is well recognized that many metabolic enzymes play essential roles in cancer cells in producing building blocks such as nucleotides, which are required in greater amounts due to their increased proliferation. On the other hand, the significance of enzymes in preventing the accumulation of their substrates is less recognized. Here, we outline the evidence and underlying mechanisms for how many metabolites normally produced in cells are highly toxic, such as metabolites containing reactive groups (e.g., methylglyoxal, 4-hydroxynonenal, and glutaconyl-CoA), or metabolites that act as competitive analogs against other metabolites (e.g., deoxyuridine triphosphate and l-2-hydroxyglutarate). Thus, if a metabolic pathway contains a toxic intermediate, then we may be able to induce accumulation and poison a cancer cell by targeting the downstream enzyme. Furthermore, this poisoning may be cancer cell selective if this pathway is overactive in a cancer cell relative to a nontransformed cell. We describe this concept as illustrated in selenocysteine metabolism and other pathways and discuss future directions in exploiting toxic metabolites to kill cancer cells.

References

  1. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14. - PubMed
  2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324:1029–33. - PubMed
  3. Yang L, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017;19:163–94. - PubMed
  4. Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006;9:358–65. - PubMed
  5. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153–61. - PubMed
  6. Fauman EB, Rai BK, Huang ES. Structure-based druggability assessment–identifying suitable targets for small molecule therapeutics. Curr Opin Chem Biol. 2011;15:463–8. - PubMed
  7. Xu D, Jalal SI, Sledge GW, Meroueh SO. Small-molecule binding sites to explore protein-protein interactions in the cancer proteome. Mol Biosyst. 2016;12:3067–87. - PubMed
  8. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2:e1600200. - PubMed
  9. Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. Cell Chem Biol. 2017;24:1161–80. - PubMed
  10. Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238:787–93. - PubMed
  11. Robinson AD, Eich ML, Varambally S. Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities. Cancer Lett. 2020;470:134–40. - PubMed
  12. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Disco. 2011;10:671–84. - PubMed
  13. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, et al. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011;43:869–74. - PubMed
  14. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010;6:551–62. - PubMed
  15. Kitatani K, Idkowiak-Baldys J, Hannun YA. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell Signal. 2008;20:1010–8. - PubMed
  16. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013;497:633–7. - PubMed
  17. Cantor JR, Abu-Remaileh M, Kanarek N, Freinkman E, Gao X, Louissaint A Jr, et al. Physiologic medium rewires cellular metabolism and reveals uric acid as an endogenous inhibitor of UMP synthase. Cell. 2017;169:258–72 e217. - PubMed
  18. Wexler P. TOXNET: an evolving web resource for toxicology and environmental health information. Toxicology. 2001;157:3–10. - PubMed
  19. Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202–13. - PubMed
  20. Burgos-Barragan G, Wit N, Meiser J, Dingler FA, Pietzke M, Mulderrig L, et al. Mammals divert endogenous genotoxic formaldehyde into one-carbon metabolism. Nature. 2017;548:549–54. - PubMed
  21. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376:1417–27. - PubMed
  22. Blackburn PR, Gass JM, Vairo FPE, Farnham KM, Atwal HK, Macklin S, et al. Maple syrup urine disease: mechanisms and management. Appl Clin Genet. 2017;10:57–66. - PubMed
  23. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30. - PubMed
  24. Possemato R, Marks KM, Shaul YD, Pacold ME, Kim D, Birsoy K, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature. 2011;476:346–50. - PubMed
  25. Sies H, Berndt C, Jones DP. Oxidative stress. Annu Rev Biochem. 2017;86:715–48. - PubMed
  26. Sarniak A, Lipinska J, Tytman K, Lipinska S. Endogenous mechanisms of reactive oxygen species (ROS) generation. Postepy Hig Med Dosw. 2016;70:1150–65. - PubMed
  27. Schecter A, Shanske W, Stenzler A, Quintilian H, Steinberg H. Acute hydrogen selenide inhalation. Chest. 1980;77:554–5. - PubMed
  28. Peyroche G, Saveanu C, Dauplais M, Lazard M, Beuneu F, Decourty L, et al. Sodium selenide toxicity is mediated by O2-dependent DNA breaks. PLoS ONE. 2012;7:e36343. - PubMed
  29. Dean E. Neonatal jaundice. Nurs Stand. 2016;30:15. - PubMed
  30. NaveenKumar SK, Thushara RM, Sundaram MS, Hemshekhar M, Paul M, Thirunavukkarasu C, et al. Unconjugated Bilirubin exerts pro-apoptotic effect on platelets via p38-MAPK activation. Sci Rep. 2015;5:15045. - PubMed
  31. Fujiwara R, Haag M, Schaeffeler E, Nies AT, Zanger UM, Schwab M. Systemic regulation of bilirubin homeostasis: potential benefits of hyperbilirubinemia. Hepatology. 2018;67:1609–19. - PubMed
  32. Cesaratto L, Calligaris SD, Vascotto C, Deganuto M, Bellarosa C, Quadrifoglio F, et al. Bilirubin-induced cell toxicity involves PTEN activation through an APE1/Ref-1-dependent pathway. J Mol Med. 2007;85:1099–112. - PubMed
  33. Rawat V, Bortolussi G, Gazzin S, Tiribelli C, Muro AF. Bilirubin-induced oxidative stress leads to DNA damage in the cerebellum of hyperbilirubinemic neonatal mice and activates DNA double-strand break repair pathways in human cells. Oxid Med Cell Longev. 2018;2018:1801243. - PubMed
  34. Iwata K, Shibuya H, Ohkawa Y, Inui N. Chromosomal aberrations in V79 cells induced by superoxide radical generated by the hypoxanthine-xanthine oxidase system. Toxicol Lett. 1984;22:75–81. - PubMed
  35. Ryu HM, Kim YJ, Oh EJ, Oh SH, Choi JY, Cho JH, et al. Hypoxanthine induces cholesterol accumulation and incites atherosclerosis in apolipoprotein E-deficient mice and cells. J Cell Mol Med. 2016;20:2160–72. - PubMed
  36. Wolf C, Bruss M, Hanisch B, Gothert M, von Kugelgen I, Molderings GJ. Molecular basis for the antiproliferative effect of agmatine in tumor cells of colonic, hepatic, and neuronal origin. Mol Pharm. 2007;71:276–83. - PubMed
  37. Mayeur C, Veuillet G, Michaud M, Raul F, Blottiere HM, Blachier F. Effects of agmatine accumulation in human colon carcinoma cells on polyamine metabolism, DNA synthesis and the cell cycle. Biochim Biophys Acta. 2005;1745:111–23. - PubMed
  38. Dewey DL. Methyl glyoxal bis guanylhydrazone abolition of the toxic action of spermidine on cells in culture. Cancer Lett. 1979;6:247–50. - PubMed
  39. Brunton VG, Grant MH, Wallace HM. Spermine toxicity and glutathione depletion in BHK-21/C13 cells. Biochem Pharm. 1990;40:1893–900. - PubMed
  40. Huber M, Poulin R. Antiproliferative effect of spermine depletion by N-cyclohexyl-1,3-diaminopropane in human breast cancer cells. Cancer Res. 1995;55:934–43. - PubMed
  41. Pegg AE. Toxicity of polyamines and their metabolic products. Chem Res Toxicol. 2013;26:1782–800. - PubMed
  42. Hiramatsu R, Hara T, Akimoto H, Takikawa O, Kawabe T, Isobe K, et al. Cinnabarinic acid generated from 3-hydroxyanthranilic acid strongly induces apoptosis in thymocytes through the generation of reactive oxygen species and the induction of caspase. J Cell Biochem. 2008;103:42–53. - PubMed
  43. Dykens JA, Sullivan SG, Stern A. Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate. Biochem Pharm. 1987;36:211–7. - PubMed
  44. Fujisawa T, Rubin B, Suzuki A, Patel PS, Gahl WA, Joshi BH, et al. Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer. PLoS ONE. 2012;7:e34437. - PubMed
  45. Jeitner TM, Renton FJ. Inhibition of the proliferation of human neural neoplastic cell lines by cysteamine. Cancer Lett. 1996;103:85–90. - PubMed
  46. Jeitner TM, Lawrence DA. Mechanisms for the cytotoxicity of cysteamine. Toxicol Sci. 2001;63:57–64. - PubMed
  47. LoPachin RM, Gavin T. Molecular mechanisms of aldehyde toxicity: a chemical perspective. Chem Res Toxicol. 2014;27:1081–91. - PubMed
  48. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 1990;186:407–21. - PubMed
  49. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15:316–28. - PubMed
  50. Shoeb M, Ansari NH, Srivastava SK, Ramana KV. 4-Hydroxynonenal in the pathogenesis and progression of human diseases. Curr Med Chem. 2014;21:230–7. - PubMed
  51. Stewart BJ, Doorn JA, Petersen DR. Residue-specific adduction of tubulin by 4-hydroxynonenal and 4-oxononenal causes cross-linking and inhibits polymerization. Chem Res Toxicol. 2007;20:1111–9. - PubMed
  52. Lee SE, Park YS. Role of lipid peroxidation-derived alpha, beta-unsaturated aldehydes in vascular dysfunction. Oxid Med Cell Longev. 2013;2013:629028. - PubMed
  53. Moghe A, Ghare S, Lamoreau B, Mohammad M, Barve S, McClain C, et al. Molecular mechanisms of acrolein toxicity: relevance to human disease. Toxicol Sci. 2015;143:242–55. - PubMed
  54. Mexas LM, Florang VR, Doorn JA. Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite. Neurotoxicology. 2011;32:471–7. - PubMed
  55. Kim D, Fiske BP, Birsoy K, Freinkman E, Kami K, Possemato RL, et al. SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature. 2015;520:363–7. - PubMed
  56. Luengo A, Abbott KL, Davidson SM, Hosios AM, Faubert B, Chan SH, et al. Reactive metabolite production is a targetable liability of glycolytic metabolism in lung cancer. Nat Commun. 2019;10:5604. - PubMed
  57. Kalapos MP. Methylglyoxal toxicity in mammals. Toxicol Lett. 1994;73:3–24. - PubMed
  58. Schalkwijk CG, Stehouwer CDA. Methylglyoxal, a highly reactive dicarbonyl compound, in diabetes, its vascular complications, and other age-related diseases. Physiol Rev. 2020;100:407–61. - PubMed
  59. Baumann T, Dunkel A, Schmid C, Schmitt S, Hiltensperger M, Lohr K, et al. Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal. Nat Immunol. 2020;21:555–66. - PubMed
  60. Brown GK, Hunt SM, Scholem R, Fowler K, Grimes A, Mercer JF, et al. beta-hydroxyisobutyryl coenzyme A deacylase deficiency: a defect in valine metabolism associated with physical malformations. Pediatrics. 1982;70:532–8. - PubMed
  61. Taniguchi K, Nonami T, Nakao A, Harada A, Kurokawa T, Sugiyama S, et al. The valine catabolic pathway in human liver: effect of cirrhosis on enzyme activities. Hepatology. 1996;24:1395–8. - PubMed
  62. Lehnert W, Sass JO. Glutaconyl-CoA is the main toxic agent in glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). Med Hypotheses. 2005;65:330–3. - PubMed
  63. Malina HZ. Xanthurenic acid provokes formation of unfolded proteins in endoplasmic reticulum of the lens epithelial cells. Biochem Biophys Res Commun. 1999;265:600–5. - PubMed
  64. Malina HZ, Richter C, Mehl M, Hess OM. Pathological apoptosis by xanthurenic acid, a tryptophan metabolite: activation of cell caspases but not cytoskeleton breakdown. BMC Physiol. 2001;1:7. - PubMed
  65. Copley SD. Shining a light on enzyme promiscuity. Curr Opin Struct Biol. 2017;47:167–75. - PubMed
  66. Jeffryes J, Strutz J, Henry C, Tyo KEJ. Metabolic in silico network expansions to predict and exploit enzyme promiscuity. Methods Mol Biol. 2019;1927:11–21. - PubMed
  67. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002;3:415–24. - PubMed
  68. Zhang D, Li J, Wang F, Hu J, Wang S, Sun Y. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett. 2014;355:176–83. - PubMed
  69. Ingraham HA, Tseng BY, Goulian M. Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine. Mol Pharm. 1982;21:211–6. - PubMed
  70. Kennedy EM, Daddacha W, Slater R, Gavegnano C, Fromentin E, Schinazi RF, et al. Abundant non-canonical dUTP found in primary human macrophages drives its frequent incorporation by HIV-1 reverse transcriptase. J Biol Chem. 2011;286:25047–55. - PubMed
  71. Curtin NJ, Harris AL, Aherne GW. Mechanism of cell death following thymidylate synthase inhibition: 2’-deoxyuridine-5’-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 1991;51:2346–52. - PubMed
  72. Richon VM, Johnston D, Sneeringer CJ, Jin L, Majer CR, Elliston K, et al. Chemogenetic analysis of human protein methyltransferases. Chem Biol Drug Des. 2011;78:199–210. - PubMed
  73. Kredich NM, Hershfield MS. S-adenosylhomocysteine toxicity in normal and adenosine kinase-deficient lymphoblasts of human origin. Proc Natl Acad Sci USA. 1979;76:2450–4. - PubMed
  74. Kredich NM, Martin DV Jr. Role of S-adenosylhomocysteine in adenosinemediated toxicity in cultured mouse T lymphoma cells. Cell. 1977;12:931–8. - PubMed
  75. Kennedy BP, Bottiglieri T, Arning E, Ziegler MG, Hansen LA, Masliah E. Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J Neural Transm (Vienna). 2004;111:547–67. - PubMed
  76. Intlekofer AM, Dematteo RG, Venneti S, Finley LW, Lu C, Judkins AR, et al. Hypoxia induces production of L-2-Hydroxyglutarate. Cell Metab. 2015;22:304–11. - PubMed
  77. Weinberg SE, Singer BD, Steinert EM, Martinez CA, Mehta MM, Martinez-Reyes I, et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. Nature. 2019;565:495–9. - PubMed
  78. Anso E, Weinberg SE, Diebold LP, Thompson BJ, Malinge S, Schumacker PT, et al. The mitochondrial respiratory chain is essential for haematopoietic stem cell function. Nat Cell Biol. 2017;19:614–25. - PubMed
  79. Kranendijk M, Struys EA, Salomons GS, Van der Knaap MS, Jakobs C. Progress in understanding 2-hydroxyglutaric acidurias. J Inherit Metab Dis. 2012;35:571–87. - PubMed
  80. Ye D, Guan KL, Xiong Y. Metabolism, activity, and targeting of D- and L-2-hydroxyglutarates. Trends Cancer. 2018;4:151–65. - PubMed
  81. Rzem R, Achouri Y, Marbaix E, Schakman O, Wiame E, Marie S, et al. A mouse model of L-2-hydroxyglutaric aciduria, a disorder of metabolite repair. PLoS ONE. 2015;10:e0119540. - PubMed
  82. Rzem R, Veiga-da-Cunha M, Noel G, Goffette S, Nassogne MC, Tabarki B, et al. A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria. Proc Natl Acad Sci USA. 2004;101:16849–54. - PubMed
  83. Hunt RJ, Granat L, McElroy GS, Ranganathan R, Chandel NS, Bateman JM. Mitochondrial stress causes neuronal dysfunction via an ATF4-dependent increase in L-2-hydroxyglutarate. J Cell Biol. 2019;218:4007–16. - PubMed
  84. Hyman SE. Neurotransmitters. Curr Biol. 2005;15:R154–8. - PubMed
  85. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012;279:1356–65. - PubMed
  86. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16:77–86. - PubMed
  87. Latini A, Borba Rosa R, Scussiato K, Llesuy S, Bello-Klein A, Wajner M. 3-Hydroxyglutaric acid induces oxidative stress and decreases the antioxidant defenses in cerebral cortex of young rats. Brain Res. 2002;956:367–73. - PubMed
  88. Kolker S, Koeller DM, Okun JG, Hoffmann GF. Pathomechanisms of neurodegeneration in glutaryl-CoA dehydrogenase deficiency. Ann Neurol. 2004;55:7–12. - PubMed
  89. Choudhury S, Borah A. Activation of NMDA receptor by elevated homocysteine in chronic liver disease contributes to encephalopathy. Med Hypotheses. 2015;85:64–7. - PubMed
  90. Bleich S, Degner D, Sperling W, Bonsch D, Thurauf N, Kornhuber J. Homocysteine as a neurotoxin in chronic alcoholism. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:453–64. - PubMed
  91. Perla-Kajan J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids. 2007;32:561–72. - PubMed
  92. Jiang SH, Hu LP, Wang X, Li J, Zhang ZG. Neurotransmitters: emerging targets in cancer. Oncogene. 2020;39:503–15. - PubMed
  93. Sarkar C, Chakroborty D, Chowdhury UR, Dasgupta PS, Basu S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res. 2008;14:2502–10. - PubMed
  94. Rao MS, Subbarao V. Dehydroepiandrosterone inhibits DNA synthesis of rat hepatocytes induced by partial hepatectomy or mitogen (ciprofibrate). Cell Prolif. 1997;30:1–5. - PubMed
  95. Safiulina D, Peet N, Seppet E, Zharkovsky A, Kaasik A. Dehydroepiandrosterone inhibits complex I of the mitochondrial respiratory chain and is neurotoxic in vitro and in vivo at high concentrations. Toxicol Sci. 2006;93:348–56. - PubMed
  96. Gil-ad I, Shtaif B, Eshet R, Maayan R, Rehavi M, Weizman A. Effect of dehydroepiandrosterone and its sulfate metabolite on neuronal cell viability in culture. Isr Med Assoc J. 2001;3:639–43. - PubMed
  97. Cheng ML, Shiao MS, Chiu DT, Weng SF, Tang HY, Ho HY. Biochemical disorders associated with antiproliferative effect of dehydroepiandrosterone in hepatoma cells as revealed by LC-based metabolomics. Biochem Pharm. 2011;82:1549–61. - PubMed
  98. Lopez-Marure R, Contreras PG, Dillon JS. Effects of dehydroepiandrosterone on proliferation, migration, and death of breast cancer cells. Eur J Pharm. 2011;660:268–74. - PubMed
  99. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004;4:604–16. - PubMed
  100. Ueda N. Ceramide-induced apoptosis in renal tubular cells: a role of mitochondria and sphingosine-1-phoshate. Int J Mol Sci. 2015;16:5076–124. - PubMed
  101. Mahoney CE, Pirman D, Chubukov V, Sleger T, Hayes S, Fan ZP, et al. A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition. Nat Commun. 2019;10:96. - PubMed
  102. Valachovic M, Garaiova M, Holic R, Hapala I. Squalene is lipotoxic to yeast cells defective in lipid droplet biogenesis. Biochem Biophys Res Commun. 2016;469:1123–8. - PubMed
  103. Csaky Z, Garaiova M, Kodedova M, Valachovic M, Sychrova H, Hapala I. Squalene lipotoxicity in a lipid droplet-less yeast mutant is linked to plasma membrane dysfunction. Yeast. 2020;37:45–62. - PubMed
  104. Tang B, Kadariya Y, Murphy ME, Kruger WD. The methionine salvage pathway compound 4-methylthio-2-oxobutanate causes apoptosis independent of down-regulation of ornithine decarboxylase. Biochem Pharm. 2006;72:806–15. - PubMed
  105. Quash G, Roch AM, Chantepie J, Michal Y, Fournet G, Dumontet C. Methional derived from 4-methylthio-2-oxobutanoate is a cellular mediator of apoptosis in BAF3 lymphoid cells. Biochem J. 1995;305(Pt 3):1017–25. - PubMed
  106. Russo P, O’Regan S. Visceral pathology of hereditary tyrosinemia type I. Am J Hum Genet. 1990;47:317–24. - PubMed
  107. Li L, Zhang Q, Yang H, Zou Q, Lai C, Jiang F, et al. Fumarylacetoacetate hydrolase knock-out rabbit model for hereditary tyrosinemia type 1. J Biol Chem. 2017;292:4755–63. - PubMed
  108. Kubo S, Sun M, Miyahara M, Umeyama K, Urakami K, Yamamoto T, et al. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proc Natl Acad Sci USA. 1998;95:9552–7. - PubMed
  109. Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet. 2001;10:1741–52. - PubMed
  110. Breiden B, Sandhoff K. Ganglioside metabolism and its inherited diseases. Methods Mol Biol. 2018;1804:97–141. - PubMed
  111. Regier DS, Proia RL, D’Azzo A, Tifft CJ. The GM1 and GM2 gangliosidoses: natural history and progress toward therapy. Pediatr Endocrinol Rev. 2016;13(Suppl 1):663–73. - PubMed
  112. Carlisle AE, Lee N, Matthew-Onabanjo AN, Spears ME, Park SJ, Youkana D, et al. Selenium detoxification is required for cancer-cell survival. Nat Metab. 2020;2:603–11. - PubMed
  113. Banerjee BD, Dwivedi S, Singh S. Acute hydrogen selenide gas poisoning admissions in one of the hospitals in Delhi, India: case report. Hum Exp Toxicol. 1997;16:276–8. - PubMed
  114. Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019;569:503–8. - PubMed
  115. Tulpule K, Dringen R. Formaldehyde in brain: an overlooked player in neurodegeneration? J Neurochem. 2013;127:7–21. - PubMed
  116. Brown AJ, Chua NK, Yan N. The shape of human squalene epoxidase expands the arsenal against cancer. Nat Commun. 2019;10:888. - PubMed
  117. Zhao HY, Ma YP. [Apoptosis effects of GM3 ganglioside on U266 cells and its possible mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018;26:1022–6. - PubMed
  118. Choi HJ, Chung TW, Kang SK, Lee YC, Ko JH, Kim JG, et al. Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression–transcriptional induction of p21(WAF1) and p27(kip1) by inhibition of PI-3K/AKT pathway. Glycobiology. 2006;16:573–83. - PubMed
  119. Yoshinaga A, Kajiya N, Oishi K, Kamada Y, Ikeda A, Chigwechokha PK, et al. NEU3 inhibitory effect of naringin suppresses cancer cell growth by attenuation of EGFR signaling through GM3 ganglioside accumulation. Eur J Pharm. 2016;782:21–9. - PubMed
  120. Kang NY, Kang SK, Lee YC, Choi HJ, Lee YS, Cho SY, et al. Transcriptional regulation of the human GD3 synthase gene expression in Fas-induced Jurkat T cells: a critical role of transcription factor NF-kappaB in regulated expression. Glycobiology. 2006;16:375–89. - PubMed
  121. Sorice M, Garofalo T, Misasi R, Manganelli V, Vona R, Malorni W. Ganglioside GD3 as a raft component in cell death regulation. Anticancer Agents Med Chem. 2012;12:376–82. - PubMed
  122. Malisan F, Testi R. GD3 ganglioside and apoptosis. Biochim Biophys Acta. 2002;1585:179–87. - PubMed

MeSH terms

Publication Types